



**2Q25**

**Results**



# Legal notice



This presentation contains forward-looking statements that are subject to risks and uncertainties. Such statements are based on the beliefs and assumptions of our management and information to which the Company currently has access. Forward-looking statements include information about our current intentions, beliefs or expectations, as well as those of the members of the Company's Board of Directors and Officers.

Disclaimers regarding forward-looking statements and information also include information about potential or expected operating results, as well as statements that are preceded, followed or that include the words "believes", "may", "will", "continues", "expects", "predicts", "intends", "plans", "estimates" or similar expressions.

Forward-looking statements and information are not guarantees of performance. They involve risks, uncertainties and assumptions because they refer to future events, depending, therefore, on events that may or may not occur. Future results and value creation for shareholders may differ significantly from those expressed or suggested by forward-looking statements. Many of the factors that will determine these results and values are beyond our ability to control or predict.

# 2Q25 Highlights



## Consolidated Net Revenue

19.3% growth, reaching R\$ 259.2 million versus 2Q24.

## Gross margin growth

In the half-year period, 0.5 p.p. growth year-on-year



Launch of 7 products in the last 12 months through internal development, partnerships and new business.

# 2Q25 Highlights 2025 Launches

## Production Animals





# NexLaner

USO VETERINÁRIO

ATENÇÃO: OBSERVAR AOS SEGUINTES PERÍODOS DE CÂMBIO:  
BOVINOS  
ANTES O ABATE DOS ANIMAIS TRATADOS COM ESTE PRODUTO  
DOMESTICOS: EVITAR O MANEJO REALIZADO 24 HORAS APÓS A ÚLTIMA APLICAÇÃO  
LÍQUIDO: ESTE PRODUTO NÃO DEVE SER APLICADO EM FÉRRAS  
PRODUTIVAS DE LITE PARA O CONSUMO HUMANO

A UTILIZAÇÃO DO PRODUTO EM CONDIÇÕES DEPARTEIS DAS  
INDICAÇÕES RECOMENDADAS PODE CAUSAR A PRESENÇA DE RESÍDUOS  
ACIMA DOS LIMITES APROVADOS, TORNANDO O ALIMENTO DE  
ORIGEM ANIMAL INAPROPRIO PARA O CONSUMO

Contém  
1 frasco com 1 L

 **ourofino**  
saúde animal

Ectoparasitida  
à base de Fluralaner  
para bovinos




## NexLaner

USO VETERINÁRIO

Ectoparasitida à base  
de Fluralaner para bovinos

INDICAÇÃO: Ectoparasitida para bovinos  
PRODUTO: Líquido - 1 L (1000 mL) - 100% Fluralaner  
NÃO APLICAR EM ANIMAIS EM ESTADO DE  
LACTAÇÃO, GESTAÇÃO E LACTAÇÃO DE FILHOS

Conteúdo: 1 L

 **ourofino**  
saúde animal





**Boostin** 25 doses

Somatotropina bovina recombinante (BST-r) de liberação lenta injetável com vitamina E

**USO VETERINÁRIO**

Contém 24 seringas com 2 g cada

**ourofino** saúde animal



# Financial Highlights



Growth in Production Animals, representing 27.8% compared to 2Q24.

Growth in International Operations, representing 19.4% compared to 6M24.



Gross margin growth of +0.5 p.p. in the half-year period




Leverage at 1.1x EBITDA, with 87.2% of debt in the long term and an average cost of debt at the end of the period of 8.20% p.a.


# Consolidated Results

- Net revenue at R\$ 259.2 million. Growth of 19.3% in 2Q25.
- In 6M25, we achieved net revenue of R\$ 448.8 million. 13.4% growth compared to 6M24.
- Gross margin increase, reaching 51.4% in the quarter.


Net revenue - R\$ million




Net revenue - R\$ million



Gross profit - R\$ million



Gross profit - R\$ million







# Production animals Results

- Net revenue at R\$ 196.8 million. Growth of 27.8% in 2Q25.
- In 6M25, we achieved net revenue of R\$ 322.3 million. This growth represents 15.3% compared to 6M24
- Gross margin increase, reaching 46.7% in the quarter.


Net revenue - R\$ million




Net revenue - R\$ million



Groos profit - R\$ million




Gross profit - R\$ million




# Companion animals Result

- Net revenue of R\$ 34.4 million, down 3.8 versus 2Q24.
- In 6M25, net revenue was R\$ 71 million. 1.9% growth compared to 6M24.
- Gross margin growth, reaching 67.6% in the quarter


Net revenue - R\$ million




Net revenue - R\$ million



Gross profit - R\$ million







Gross profit - R\$ million



# International operations Result

- Net revenue of R\$ 28 million, up 1.7% versus 2Q24.
- In 6M25, net revenue was R\$ 55.5 million. 19.4% growth compared to 6M24.
- Gross margin growth, reaching 64.6% in the quarter




# Adjusted SG&A

- Adjusted SG&A amounted to R\$ 77.3 million, representing 29.8% of net revenue, dropping 2.2% over net revenue.
- Impacted by strategic investments in commercial and marketing structures. In line with the growth plan of the business units


SG&A - R\$ million

(%) Net revenue



SG&A - R\$ million


(%) Net revenue



# Investment in RDI

- R&D investments reached 8.8% of net revenue in 1H25, totaling R\$ 39.6 million.
- The invested amount is in line with the strategy of expanding the product portfolio with the aim of ensuring future revenue and generating value for the company.


Research and Development Expenditure - R\$ million



# Adjusted EBITDA

- Adjusted EBITDA showed a 26.5% growth versus 2Q24.

Adjusted EBITDA R\$ million



18.5%

15.0%

18.1%

19.2%


Adjusted EBITDA Margin



# Cash Generation

Operating cash generation reaching R\$ 50.5 million in the first half of the year, totaling cash availability of R\$ 147.6 million.

Capital reduction implemented in January 2025\*.




\*It should be noted that on January 31, 2025, as previously announced and approved at the Extraordinary Shareholders' Meeting held in October 2024, we paid out the capital reduction in the amount of R\$ 120 million to the shareholders. This move is in line with our strategy of creating value for all shareholders, without undermining the company's growth or investment capacity, in line with the leverage of the last four years.


With our robust cash generation, in the first few months of the year, we were able to reintegrate practically 50% of the value distributed to shareholders. We thus reaffirm the operation's strong cash generation and conversion capacity, as well as the efficiency of financial management, which ensures a solid structure aligned with Ourofino's strategic needs.

# Capital structure

Leverage at 1.1x EBITDA, and an average cost of debt at the end of the period of 8.20% p.a.,




## Composition




# Capital structure

87.2% of debt  
over 5 years

Aging - R\$ million



Indebtedness Aging - R\$ million



# Q&A

## Reimagining animal health

We produce solutions  
and services to feed the  
world and increase the  
longevity of companion  
animals.





**Ourofino S.A.**  
**(B3:OFSA3)**

Investor Relations Department



[ri@ourofino.com](mailto:ri@ourofino.com)



(16) 3518-4098



[ri.ourofino.com](http://ri.ourofino.com)

Marcelo Silva

Lucas Britto